secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001193125-25-291352
Event type: debt
Sentiment:  neutral
Materiality: 0.35
Item codes: 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share
--------------------------------------------------------------------------

- K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.
- Conversion was exercised under loan agreement dated May 9, 2025, as amended November 4, 2025.
- Shares were issued in reliance on Section 4(a)(2) exemption from registration.
- Total conversion right under loan agreement remains up to $12.5M; $10M principal remains convertible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525291352/0001193125-25-291352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525291352/d873320d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer